INTRODUCTION
Associations between height and cancer risk have been reported in a number of prospective studies (1, 2) . Taller individuals appear to be at increased risk. Furthermore, ecologic analyses indicate that geographic patterns of cancer incidence and mortality are associated with variations in population height (3) (4) (5) . The most consistent associations have been found in relation to breast cancer (6) (7) (8) , although associations have also been reported for many other cancer sites. Therefore, common mechanisms may underlie these associations, but their precise nature remains unclear.
Models of cancer pathogenesis suggest that cancer arises as a result of DNA damage at a number of specific loci important in the regulation of the cell cycle or DNA repair (9, 10) . While specific oncogenes, tumor suppresser genes, and cancer susceptibility genes have been identified, it has become increasingly apparent that epigenetic pathways also underlie the development of some malignancies. Several mechanisms may be common to many different cancers. For example, angiogenesis (the formation of new blood vessels) is an absolute requirement for the growth of all solid tumors (11) . Similarly, apoptosis is a mechanism for eliminating damaged or dangerous cells from the body, and thus it provides a natural defense against cancer. The most potent cell survival factor controlling apoptosis is insulin-like growth factor I (IGF-I). Raised levels of IGF-I and reduced levels of its main binding protein, insulin-like growth factor (IGF)-binding protein 3, may diminish this defense against a range of cancers. In support of this notion, recent prospective research has demonstrated that raised levels of IGF-I are associated with increased risks of prostate (12) (13) (14) , breast (15) , and colorectal (16, 17) cancers.
While a number of reviews have synthesized results from studies reporting associations between height and breast (6) (7) (8) , colorectal (18) , and thyroid (19) cancer, and some have examined associations across a limited range of cancers (20) , none have attempted to describe such associations across all cancer sites. In this review, we have aimed to 1) synthesize the evidence linking height to site-specific cancers and 2) review possible mechanisms underlying the observed associations. While most studies have focused on associations between overall height and cancer risk, a few have also investigated associations of the two main components of height-leg length and trunk length-with cancer risk. Leg length is a marker for growth before puberty, since prepubertal increases in stature arise more from increases in leg length than from increases in trunk length. This is demonstrated by changes in the ratio of sitting height (mainly trunk length) to height during growth. At birth, the ratio is approximately 0.66, but by puberty it has declined to 0.52 (21) . Thus, studies examining the relation of cancer risk to the components of stature-trunk length and leg length-may indicate periods during childhood growth when risk factors underlying height-cancer associations operate (22) (23) (24) . Therefore, we have included such studies in this review.
SEARCH STRATEGY
We systematically searched MEDLINE databases (US National Library of Medicine) for all relevant articles published between 1966 and 2000. The search strategy used was as follows: ["body height" or "height" or "anthropometry" or "skeletal formation" or "leg length" or "sitting height" or "body constitution" or "body composition"] AND ["neoplasms" or "cancer" or [the name of any site-specific neoplasm] ]. Terms shown in italic type were used as keywords; the remainder were mapped to Medical Subject Headings. Where the title of an article suggested that height-cancer relations might be presented, the abstract was reviewed by hand. Both English-language and non-English-language papers were reviewed. In cases where no results for height or leg length were mentioned in the abstract of a paper, the full article was examined to determine whether it should be included in the review. Relevant papers cited in the retrieved articles were also obtained.
Presentation of findings
Because of the large number of studies identified, we restricted our tabulations to cohort studies and nested casecontrol studies, since these types of studies are less prone to bias than case-control studies. We refer to nested casecontrol studies as cohort studies throughout this paper. Results of case-control studies are summarized; a summary 314 Gunnell et al. of these findings is available from the authors upon request. Few studies have examined the relation of components of stature-leg length and sitting height-to cancer risk; we tabulated the findings for all of these studies.
Smoking may confound height-cancer associations, since smoking, height, and cancer incidence are all socially patterned. Therefore, we have presented height associations separately for cancers in which smoking is not thought to play an important etiologic role and those in which it is. In these latter studies, failure to adequately control for smoking may lead to biased estimates of height-cancer associations. We did not review studies examining associations of height with all cancer sites combined.
All imperial units were converted to metric units. Relative risks are presented for taller groups compared with shorter (reference) groups. Where risks were presented in relation to a decrease in stature in the source publication, the inverse of the relative risk was computed. Relative risks are reported according to the number of decimal places used in the original paper; we rounded these to two decimal places if more than two decimal places were given in the data reported.
Height-cancer associations for cancers in which smoking is not thought to be of etiologic importance
Colorectal cancer. Table 1 summarizes the results of 16 cohort or nested case-control studies that have reported on associations between height and colorectal cancer (1, 2, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . Seven of the cohort studies reviewed reported that greater stature was associated with increased cancer risk. A 20-60 percent increased risk among persons in the top height categories compared with those in the bottom categories was seen in most studies. There were no consistent differences in the associations according to gender or cancer site (colon or rectum) or according to whether mortality or incident disease was examined. In studies that controlled for socioeconomic position (2, 29) , there was no clear evidence of socioeconomic confounding. In the three studies in which data were controlled for weight or body mass index, this adjustment led to a partial attenuation of the height-cancer associations (1, 27, 33) .
We identified 15 case-control studies reporting on heightcolorectal cancer associations. Two of these reported statistically significantly (p < 0.05) increased risks among taller individuals (38, 39) . In one study, associations were seen in North American patients but not in Chinese patients (39) . Three studies (40) (41) (42) found some evidence of increased risks (odds ratios > 1.2) among taller men or women, but these effects were not statistically significant at the 5 percent level. The remaining 10 case-control studies (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) , including some with over 200 cases (46, (48) (49) (50) (51) , showed no height-cancer associations. In contrast, a meta-analysis of 13 case-control studies with a combined total of 5,287 cases of colorectal cancer reported weak but consistent heightcancer associations in males and females (18) . The odds ratio in the top quintile of height compared with the bottom quintile was 1.31 (95 percent 19) . Surprisingly, only two of the 13 case-control studies on which this meta-analysis was based (44, 50) had published their findings regarding height-cancer associations separately.
Prostate cancer. Twenty-two reports on nested casecontrol or cohort studies (1,2, 13, 14, 24-26, 28, 29, 31, 53-64) described associations between height and prostate cancer (table 2) . Some of these reports were based on longer follow-ups of the same cohort, and in some there may have been overlap in the populations studied (24-26, 28, 53-55, 58, 64) . Where relative risks were specified, with the exception of two studies (61, 64) , risks were all greater than 1.0 in the taller height categories. Most studies reported a 20-40 percent increased risk in the top height groupings compared with the bottom groups. Controlling for possible socioeconomic confounding attenuated the associations in the two cohorts reporting positive associations that examined this issue (29, 60) . Height-prostate cancer associations were also apparent within the relatively socially homogenous US Physicians and Health Professionals cohorts (1, 56) . As was seen with colorectal cancer, adjustment for measures of adiposity partially attenuated observed associations in two (1, 31) of the three (1, 31, 56) cohorts where its possible confounding effect was assessed. In the Kaiser Permanente cohort, race and year of birth appeared to strongly confound height-cancer associations (62) . Adjustment for these factors resulted in a reduction in the relative risk in the tall group (versus the short group) from 1.45 (95 percent CI: 1.26, 1.67) to 1.15 (95 percent CI: 1.00, 1.33). In the one study where incidence and mortality associations were compared, associations were stronger for cancer mortality than for cancer incidence (59) . This effect may have been due to the greater preponderance of screen-detected, localized cases among persons with incident (nonfatal) prostate cancer; many of such cancers may never become invasive. Inclusion of these cases dilutes the pool of "true" (invasive) cases and leads to measurement error in effect estimates. This effect may explain the stronger associations with advanced disease reported for one cohort (56) . However, in the other two studies that compared height-cancer associations among persons with advanced disease with all cases, little difference in effect sizes was seen (61, 62) .
Of the 24 case-control studies examining height-prostate cancer associations, two reported associations that were statistically significant at the 5 percent level (65, 66) . In one of these (65), significant associations were seen in US Whites but not in Blacks. Six papers based on five studies (40, (67) (68) (69) (70) (71) reported positive associations with height (odds ratios > 1.2) that did not reach conventional levels of statistical significance. One study reported a significant protective effect of height, but control patients in this study were men with prostatic hyperplasia (control selection bias) (72) . The remaining 16 case-control studies, some based on over 1,000 cases, found no clear relation with height (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) .
Breast cancer. Twenty-four papers describing cohort and nested case-control studies have reported on associations between height and breast cancer (table 3) (2, 24, 25, 31, (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) (107) (108) . Some of these papers were based on longer follow-ups of the same cohort, and in others there was a possibility of overlap in the cases studied (24, (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) . Most studies examined incident disease, including deaths. Where reported, relative risks in relation to increasing height were greater than 1.0 in all but one of the studies (2). Interestingly, this was the only study in which deaths alone were included in the analysis (2) , and this may indicate that higher mortality rates among persons from lower socioeconomic (shorter) groups attenuated any association with height. Increased risks of approximately 10-60 percent were seen in the top height categories compared with the bottom categories. Eleven studies distinguished premenopausal cancers from postmenopausal cancers. Associations were stronger in relation to postmenopausal cancer risk in seven of these studies (based on six cohorts), but the differences were often small. This is in keeping with a pooled analysis of data from seven prospective studies that reported relative risks, per 5-cm increase in height, of 1.02 (95 percent CI: 0.96, 1.10) for premenopausal cancer and 1.07 (95 percent CI: 1.03, 1.12) for postmenopausal cancer (109) . In this pooled analysis, associations with height were stronger among women whose mothers had had breast cancer (p for interaction = 0.005), indicating the possible importance of genetic factors in height-cancer associations (109) .
Three papers reported relative risks before and after adjustment for, among other factors, weight or body mass index. In one of these, the height association became nonsignificant at the 10 percent level of statistical significance after adjustment (31) ; in the other two, no consistent effects of adjustment were seen (91, 99) . In a pooled analysis, there was weak evidence {p for interaction = 0.12) that height associations were stronger among persons with low body mass indexes (109) . In the two papers reporting results from models that controlled for socioeconomic position, there was little or no evidence of confounding (91, 98) .
Seventy-four published case-control studies had investigated height-breast cancer associations. Of these, 22 reported statistically significant positive associations with increasing height in at least one of the groups examined . A further 15 studies found some evidence of increased risks (odds ratio > 1.2 in the tallest group), but these increases did not reach conventional levels of statistical significance (132) (133) (134) (135) (136) (137) (138) (139) (140) (141) (142) (143) (144) (145) (146) . Four studies reported a significantly reduced risk associated with increased height (147) (148) (149) (150) . The remaining 33 studies (40, showed no association. A pooled analysis of 12 case-control studies indicated that height was associated with a greater risk of premenopausal cancer than of postmenopausal cancer (8) . The relative risk in the top quintile of height versus the bottom quintile was 1.41 {p = 0.004) for premenopausal cancer and 1.11 (p = 0.20) for postmenopausal cancer. This differential effect was not consistently seen, however, across the range of studies reviewed and is in the direction opposite of that reported in the pooled analysis of cohort studies (109) .
Endometrial/uterine cancer. Height-endometrial cancer associations have been assessed in six cohort studies (table  4) (24, 31, (183) (184) (185) (186) . Positive associations were seen in three of these (183) (184) (185) . In one study in which positive associations were reported, effects were stronger among persons with raised body mass indexes (184) , and in another the associations were restricted to those with postmenopausal cancer (185) .
Seventeen case-control studies described in 18 papers were identified. In only three of these studies were statistically significant increased risks seen among taller individuals (187) (188) (189) . In the analysis by Goodman et al. (189) , the increased risk was greatly attenuated after data were controlled for weight (the odds ratio in the top quartile of height declined from 1.8 to 1.3). A further five studies suggested an association with increasing height (191) (192) (193) (194) (195) , but these findings did not reach the 5 percent level of statistical significance. In one of these studies, there was a suggestion that height-cancer associations were more marked among overweight women (192) . Ten studies found no evidence of increased risk among taller women (40, (196) (197) (198) (199) (200) (201) (202) (203) (204) . One case-control study found that greater stature was associated with reduced risk (40, 201) .
Other cancers not caused by smoking. Table 5 summarizes results from prospective investigations of other types of cancers not thought to be caused by smoking. Three (2, 29, 205) of the five cohort studies (2, 25, 29, 31, 205) investigating height associations with hematopoietic cancers suggested that taller individuals are at an increased risk; this trend persisted after adjustment for socioeconomic position (2, 29) and body mass index (205) . Two case-control studies of adults have examined height-hematopoietic cancer associations (40, 206) . One reported a positive association with Hodgkin's lymphoma (206) ; the other found no evidence of associations with Hodgkin's or non-Hodgkin's lymphoma and found a nonsignificant inverse association with myeloma (40) . Two case-control studies of childhood leukemia were also inconclusive (207, 208) . A number of other studies compared the heights of children with hematopoietic cancer with population norms (209) (210) (211) (212) (213) (214) , but these findings are difficult to interpret, because the population data used for comparison were often based on values for children's heights some years before the study period and thus took no account of secular increases in stature. Furthermore, the growth of children with cancer may be influenced both by cancer itself and by the effects on growth of the treatment they receive.
Six cohort studies (2, 25, 26, 29, 31, 215) and seven casecontrol studies (40, 46, (216) (217) (218) (219) (220) have investigated associations between height and stomach cancer. Results of one of the six cohort studies suggested that greater stature was associated with decreased risk (2) ; the other cohort studies showed no significant association. Two (217, 220) of the seven case-control studies showed an inverse association between height and cancer risk in men and women. By contrast, in a Chinese case-control study, greater stature was associated with a threefold increased risk in females but not in males (218) . The other four studies showed no clear patterns of association (40, 46, 216, 219) .
Associations of height with central nervous system tumors were examined in four cohort studies (25, 29, 31, 221) and one case-control study (222) . One of the cohort studies indicated an increased risk with increased height (221) , and another suggested a borderline increased risk in taller individuals (29) . The only case-control study we iden- iian Japanese males (28) iian males (27) 101 colon, 63 rectum; incident cases 726 colorectum; incident cases iian males (26) rd and University of Pennsylvania mni (males) (25) ES I" (males and females) (24) s' Health Study (females) (32) h male corporate employees (33) cohort (females) (34) tified that examined the association of height with central nervous system tumors was based on only 74 cases and indicated that short stature was associated with increased risk (222) ; however, it is difficult to interpret studies examining associations between height and childhood cancers, since the tumor itself may influence growth. Four cohort studies (25, 64, 223, 224) and three case-control studies (225, 226, 273) have examined associations with testicular cancer. The largest of the cohort studies (224) and one of the casecontrol studies (226) showed strong evidence of a greater risk in taller people. Two (227, 228) of the three cohort studies (25, 227, 228) examining malignant melanoma risk factors reported positive associations with height. One (31) of the two (24, 31) cohort studies and all three case-control studies (40, 149, 229) of cervical cancer showed inverse associations with height. These associations remained after adjustment for an array of possible socioeconomic and reproductive confounding factors (40, 229) . Other prospective studies have suggested that there are no strong height associations with gallbladder or cystic duct cancers (35) .
Four prospective studies (2, (230) (231) (232) have grouped together all cancers not thought to be related to smoking. Three of these studies indicated an increased risk in taller individuals that was not attenuated by controlling for possible socioeconomic confounding (2, 230, 232) .
Other case-control studies. A meta-analysis of 12 casecontrol studies investigating risk factors for thyroid cancer (19) reported positive associations between height and cancer risk in men and women. The pooled estimated of risk per 5-cm increase in height was 1.08 (95 percent CI: 1.03, 1.13). Surprisingly, height-thyroid cancer associations were presented separately in only one (233, 234) of these 12 studies when findings were originally published. Four studies of male breast cancer have reported on associations with height (235) (236) (237) (238) . All four studies provided some evidence of increased risk with increasing height, although the evidence reached conventional levels of statistical significance in only one (235) . Five case-control studies have examined heightovarian cancer associations (40, (239) (240) (241) (242) ; there was probably some overlap in cases and controls in two of them (241, 242) . No consistent picture was seen. One study reported a statistically significant inverse trend (p < 0.01) (40) , and weak (nonsignificant) evidence of increased risk among taller women was seen in two Japanese reports (241, 242) . For bone tumors, one study of adults suggested that risk increases with height (243); one (244) of the two studies of children (244, 245) reported similar effects, but in that study the control population was children with other cancers. The findings from case series that used population height norms for comparison were unreliable (246) (247) (248) . One study showed a positive association between height and vaginal cancer (249) . For liver cancer, one study examining this cancer reported inverse associations with height (40), but another study did not (250) . Inverse associations with height were also reported in women but not in men in one case-control study of soft tissue sarcoma (251) ; in the two other case-control studies of this cancer (252, 253) , no clear association was reported, although trends consistent with increasing risk with height were seen in the smallest study (252 (53) rd and University of Pennsylvania mni (25) iian Japanese (28) iian males (26) iian Household Survey (54) 
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. Results of prospective studies reporting on the association between height and endometriai/uterine cancer (table 6) . Five of the six cohort studies that presented their results as relative risks showed that risks were all greater than 1, although only one of these was statistically significant at conventional levels (254) . In several studies (24, 29, 256) , the possible confounding effects of smoking were not controlled for.
One (259) of the three case-control studies (257-259) indicated that among smokers, shorter stature was associated with increased risk in males and females, with a difference in mean heights of 1 cm. In contrast, in another of these studies there was a suggestion that greater stature in women was associated with increased risk (257) .
Other cancers caused by smoking. Table 7 summarizes findings from cohort studies that have examined the associations of height with other smoking-related cancers. Two (29, 215) of the four cohort studies (25, 29, 31, 215) reporting associations with esophageal cancer demonstrated reductions in risk with increasing height. Neither of these analyses controlled for smoking. Similar findings were reported in the four case-control studies that examined this issue (40, 219, 220, 260) . In two of these studies, each with approximately 300 cases, strong associations were seen in models adjusted for smoking (219, 220) . In one of these studies, associations were seen for adenocarcinoma but not for squamous cell carcinoma (220) .
The cohort studies examining pancreatic cancer (25, 29, 31, 35, 261) found no clear pattern of association with height, although one (262) of the five case-control studies (40, 190, 262, 263, 335) found evidence of greater risk among taller women. A pooled analysis of five case-control studies found some evidence of increasing risk with greater height: The relative risk in the tallest quintile was 1.35 (95 percent CI: 0.87, 2.09), and the test for linear trend was not significant at conventional levels (p = 0.12) (336) . The four cohort studies that examined bladder cancer showed no clear pattern of association with respect to height (24, 25, 29, 31) . Neither of the two case-control studies (40, 264) examining this issue showed strong effects, although in an Italian case-control study there was some evidence of increasing risk with height in females (40) . An increased risk of renal carcinoma in taller males was reported in one (31) of two cohort studies (25, 31) examining this issue. The five case-control studies that presented data on height-renal cancer associations (40, (265) (266) (267) (268) provided no evidence of height effects, although in one (40), a twofold increased risk was seen in the tallest men and the opposite effect was seen in women. In the two case-control studies that examined associations between stature and carcinoma of the larynx (40, 260) , one reported no evidence of an influence of height on cancer risk in men (40) . In the other, which examined risk in men and women combined, risk increased with decreasing stature, but effects were attenuated and nonsignificant after data were controlled for (among other factors) smoking (260) . The same study reported associations between reduced stature and oropharyngeal cancer risk in men and women. Again, associations were greatly attenuated but remained significant (p < 0.001) after data were controlled for smoking differences (260) .
In three prospective studies (2, 230, 231) (table 7) and two case-control studies (269, 270) , all smoking-related cancers were grouped together. None of these studies found an association between height and smoking-related cancers.
Components of height and cancer risk
Cohort studies. Seven research papers based on three cohorts (22, 24, 26, 89, 128, 232, 271) (24, 89, 128) indicated either that leg length and sitting height were equally related to risk (prostate, colorectal, bladder, and uterine cancers) or that leg length was the component of stature associated with increased risks (lung, breast, and cervical cancers) (24) . Neither of the two analyses of the Honolulu Heart Program cohort showed significant associations with leg length or sitting height (26, 271) , although the earlier analysis of prostate cancer risk suggested that leg length was associated more strongly with increased risk than was sitting height (26) . Two published articles based on the Boyd Orr cohort assessed associations between the components of stature, measured in childhood, and later cancer risk (22, 232) . In the first paper, no significant associations were reported, although leg length appeared to be more strongly associated with risk than did sitting height (232) . More recently, a subgroup analysis based on persons who were aged <8 years when they were measured in childhood indicated that those with longer legs, but not those with longer trunks, were at greater risk of death from cancers not thought to be related to smoking (22) .
Case-control studies. Eight case-control studies have investigated associations between the components of height and cancer risk (84, 86, 128, 149, 161, 197, 272, 273) (table  9) . In all but one (273) of these studies, sitting height was measured and differences were reported with respect to sitting height or the sitting heightheight ratio. High values for this ratio indicate a long trunk relative to total height, and hence relatively short legs. In three studies, the source of controls is likely to have resulted in selection biases (84, 86, 149) . In one of these studies, controls were approximately 15 years younger than cases (149) ; in the other two (both by the same group of investigators (84, 86) ), urology clinic patients were used as controls. Two of the remaining five investigations indicated that leg length was the component of stature associated with increased risk of breast cancer (128) and testicular cancer (273) . In Swanson et al.'s investigation of endometrial cancer (197) , there was no association with overall height but there was a significant decreased risk with increasing sitting height, which suggests that leg length was associated with increased risk. A further study based on postmortem examination of children who died from leukemia indicated some disproportion in the cases (272) . Reanalysis of the original data tabulated in that paper (25) itehall Study males (leukemia and ymphoma) (29) kjavik Study (males and females) leukemia and lymphoma) (31) rses' Health Study (females) non-Hodgkin's lymphoma) (205) 
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(data not shown) indicates that cases had shorter legs relative to their sitting height, although effects of treatment on growth cannot be ruled out.
DISCUSSION OF MAIN FINDINGS
Most prospective studies reporting associations between height and cancer have shown either that risk increases with stature or that there is no significant relation. Evidence from case-control studies is considerably weaker, but meta-analysis of their findings in relation to thyroid, breast, pancreatic, and colorectal cancer suggests a general pattern of increasing risk with greater stature (8, 18, 19, 336) . Associations are similar in men and women and have been reported for a range of cancer sites-particularly for breast, prostate, colorectal, and hematopoietic cancers-but they are also seen with central nervous system tumors, malignant melanoma, endometrial cancer, and thyroid cancer. In the relatively few studies in which multivariable analyses have been carried out to control for the possible confounding effects of socioeconomic position and indicators of adiposity, the observed associations are sometimes but not generally attenuated. For breast cancer, there is some evidence that height associations are stronger in persons of lower weight (109) , whereas the opposite has been reported for endometrial cancer (184) . Associations are seen in relation to both cancer incidence and cancer mortality, indicating that survival bias is unlikely to explain the associations observed. The strength of association in studies with positive effects is relatively weak; there is usually, at most, a 20-60 percent increased risk in the tallest groups compared with the shortest. The magnitude of increased risk is similar for the three most common cancers not caused by smoking: colorectal cancer, prostate cancer, and breast cancer. Associations of stature with smokingrelated cancers are more difficult to interpret, since many of these studies have not controlled for the potentially confounding effects of tobacco smoking.
Few studies have examined associations between the components of stature and cancer risk. Although the evidence in this area is weak, the component of height more often associated with increased risk is leg length. Leg length is a marker for growth before puberty, since prepubertal increases in stature arise more from increases in leg length than increases in trunk length. This suggests that the biologic mechanisms underlying the relation between height and cancer may have their origins in factors which influence long bone growth in childhood.
The range of studies reporting height-cancer associations suggests either a common underlying mechanism or bias in the studies reviewed. Therefore, before we discuss possible mechanisms for the observed associations, alternative explanations will be considered.
Chance and bias
Many large cohort studies and a number of case-control studies have reported on height-cancer associations, which indicates that these findings are unlikely to be due to chance alone. While bias is an important consideration in epidemi- ologic research, cohort studies-the results of which we have given the most emphasis to-are less prone to selection and information biases that often beset other observational designs.
Methodological bias in the reported studies. Five possible sources of bias in the conduct of the studies reviewed here must be considered. First, detection bias would arise if cancer were more likely to be identified in taller individuals. This might occur because taller (affluent) individuals are more likely to undergo health screening. Such an effect would lead to stronger associations for incident (screendetected) disease compared with fatal disease, under the assumption that some screen-detected cancers would not have been fatal or were detected earlier in taller individuals. The example of prostate cancer provides us with an opportunity to assess this possibility. With the advent of prostate cancer screening, one might expect height associations to be stronger for incidence than for mortality, because of the greater chance of detecting incidental cancers in individuals who undergo screening and the fact that individuals who request screening tend to be more affluent (taller). However, if anything, the opposite effect is seen for prostate cancer (59) . More generally, in the papers reviewed, the associations are similar for incidence and mortality, making detection bias unlikely.
Second, survival bias might arise in studies examining cancer mortality rather than incidence if stature were a marker of the chances of surviving once cancer had been diagnosed, rather than a marker of cancer risk per se. Such an effect might be expected to diminish rather than increase height-cancer associations, since higher socioeconomic position is associated with both greater stature and better prospects of cancer survival (274) . Interestingly, in the breast cancer cohorts (see table 3), the only study not to show a positive association with height was the one based on deaths alone (2).
Third, measurement bias would occur if there were systematic differences in the measurement or reporting of stature among those who were to go on to become cases. At the time of measurement in cohort studies, observers are unlikely to be aware of subjects' likelihood of developing cancer. While measurement error may arise when height assessment is based on self-reports rather than on measurements, such errors are likely to be nondifferential with respect to later cancer occurrence, and this is likely to attenuate associations. Furthermore, since shorter individuals tend to overreport their height, any height-cancer associations found are likely to be attenuated (275) .
Fourth, it has been suggested that height-cancer associations may arise because cancer risk increases with age and taller individuals are more likely to live longer (276) . While this phenomenon may influence the findings of some studies, it is unlikely to explain associations seen with cancers in young people (such as premenopausal breast cancer and testicular cancer). In addition, the statistical methods used in some analyses (Cox's proportional hazards models) ensure that persons who die of cancer are compared only with persons of the same age who are alive at the time cancer is detected or cancer death occurs (277). of prospective studies reporting on the associations between components of height (leg length, sitting height, and trunk length) Lastly, case-control studies may be subject to control selection biases. In some studies, control subjects were chosen from patients with other cancers (79, 117, 164, 258) or from persons with other conditions that may themselves be associated with height (46, 251) . This bias could work in different directions depending on height-disease associations in the control population.
Results
Publication bias. The final type of bias that should be considered is publication bias. The relatively high proportion of positive findings in the studies reviewed here could reflect such an effect. Many of the cohort studies reporting site-specific height-cancer associations have not reported on cancer at other sites. However, a number of studies carried out in larger cohorts-the Whitehall (29), Reykjavik (31), US Physicians (1), and Renfrew and Paisley (2) cohorts, the Norwegian tuberculosis screening cohort (35, 215, 227) , and the Nurses' Health Study cohort (32, 91, 205) -have reported associations between height and cancer at a range of sites, and this increases confidence in such findings' not being a result of publication bias alone. Publication bias is more likely to be a concern with cancer sites that have been examined in only one or two articles. An example of this phenomenon is seen with the strong positive association reported in the one case-control study examining the relation between height and vaginal cancer (249) . Only one (233) of 12 case-control studies (19) investigating the etiology of thyroid cancer presented height-cancer associations when results were published; however, a recent meta-analysis of these studies (19) , using data obtained from the investigators, confirmed that height was associated with increased risk in most of the studies but the association had not been reported.
Thus, chance and bias appear unlikely to explain reported height-cancer associations. Below, we outline possible explanations for the observed relation. The explanations can be divided into two basic categories: 1) height as a biomarker for other exposures that influence cancer risk and 2) height as a biomarker for biologic mediators of risk.
Previously identified confounders
The roles of several possible confounding factors, particularly body mass index, socioeconomic position, and smoking, have been investigated in the studies included in this review. Controlling for these factors in multivariable analyses only partially attenuates the height-cancer associations reported, or even strengthens them (1, 2, 29, 31, 33, 60, 91, 98, 99, 128) . While it is possible that residual confounding remains in some of these analyses as a result of the relatively crude adjustments made, in most cases the attenuation of risk is slight (or nonexistent), indicating a residual height "effect." Socioeconomic position, like height, is a marker for a range of exposures, some of which may influence height. Interpretation of the effects of controlling for socioeconomic position in models examining height-cancer associations is therefore not straightforward.
Some of the observed associations may arise as a result of failure to control for other important confounders, and in some analyses there is little assessment of possible confound-9. Results of case-control studies reporting on the associations between components of height (leg length and sitting height) and cancer Case-control ing structures. For example, the increased risk of esophageal cancer among shorter individuals (29, 215 ) may be confounded by smoking. Below, we describe other factors that may confound or explain height-cancer associations.
Height as a biomarker for genotype or environmental exposures
Height per se clearly does not cause cancer. In the associations reported here, it is simply acting as a biomarker for some other exposure(s). Thus, strictly speaking, the heightcancer associations could be considered confounded by these factors; however, since these factors are as yet undetermined and we have ruled out confounding by social class, smoking, and body mass index (see above), height may be considered a biomarker for this (these) unknown etiologic factor(s). To assess possible candidates for these exposures, it is important to first consider genetic and environmental influences on growth and hence final adult height and their relation to the etiology of cancer.
Genetic influences on height. Twin studies highlight genetic influences on stature. Correlations between the adult heights of monozygotic twins are approximately 0.90, as compared with 0.50 for dizygotic twins (278, 279) . These differences probably exaggerate the genetic contribution to height, since in-utero (environmental) influences on growth and pregnancy outcome differ for monozygotic twins and dizygotic twins (280) . The particular influence of the intrauterine environment on later growth is highlighted by studies demonstrating height differences of over 1 cm among 6-year-old monozygotic twins who were discordant for birth weight (278) .
The relative contribution of genetic and environmental factors to adult height depends on the degree of environmental adversity experienced during growth. A twin study from Finland highlights this by showing that the genetic contribution to adult height differences increased in the first half of the 20th century, presumably as a result of environmental improvements' reducing this source of variation (279) . Likewise, parent-child correlations for stature are higher in well-nourished nations than in poorly nourished nations; in the latter countries, environmental adversity may override genetic influences (281) .
Growth and final adult height are influenced by a number of genes. It is likely that prepubertal growth, the timing of puberty, and peak height velocity are under separate genetic control. The range of genes involved in growth is highlighted by the number of specific genes involved in growth disorders. These include the GH-1 (282), SHOX (283), FMR1 (284) , and GHRHR (285) genes. While it is possible that a gene which is important in growth is closely linked to one that influences cancer risk, height-cancer associations have been reported in dizygotic twins who are discordant for adult height (273) . To fully assess this issue, however, studies of cancer risk in relation to height in monozygotic twins would be required; to date, no such studies seem to have been conducted.
Environmental influences on height. The three main environmental factors influencing childhood growth are diet, ill health, and psychological well-being (286) . Some of these factors may have long-term influences on cancer risk.
It has long been recognized that animals on calorierestricted diets are smaller, live longer, and have a reduced incidence of cancer (287, 288) . A recent analysis suggests that in humans, a lower calorie intake in childhood is also associated with reduced cancer risk (289) . Therefore, it is possible that stature acts as a biomarker either for diets which protect against cancer (short stature) or diets which are associated with an increased risk of cancer (tallness). The importance of prepubertal diet and growth is supported by the observation that height-cancer associations appear to be strongest among birth cohorts exposed to periods of food shortage during the prepubertal growth period (97, 290) . Likewise, the stronger associations with leg length suggest that nutritional status before puberty may be most important, since leg length is the component of stature responsible for the greatest amount of prepubertal growth and thus may be a more sensitive marker of nutritional influences at that time.
A number of pathogens are known to be important in the etiology of cancer (291) , and prolonged illness with such infections in childhood may lead to stunting (292, 293) . Infection with Helicobacter pylori may underlie the increased risk of stomach cancer seen among shorter individuals in some studies (2, 217, 220) , since it is important in the etiology of stomach cancer and is associated with poor childhood growth (294, 295) . For most cancers, however, risk increases with stature. Greater height may reflect a lower infection load in childhood, and this may have two consequences in relation to cancer risk. First, it may leave older children susceptible to infections that, if experienced in later life rather than in early childhood, carry a greater risk of malignancy. Second, it may lead to a more generalized underdevelopment of immune function. In support of these notions, it has been shown that risk of lymphoma is increased among individuals from small families (2, 296) ; small family size is, in turn, associated with greater stature.
Psychological stress in childhood may influence growth, leading to short stature (297, 298) . However, it is unlikely that this could underlie the association between greater stature and cancer risk, unless childhood stress protects against later cancer risk.
Height as a biomarker of exposures in utero, childhood growth, and the timing of puberty
Associations between birth weight and the risks of breast and prostate cancer have been reported in some studies (299, 300) . These associations may reflect the influence of fetal nutrition, pregnancy steroids, or maternal growth factors on long-term cancer risk (301) . Since birth weight is associated with height later in life (correlations between birth weight and adult height of 0.22-0.26 have been reported (302, 303) ), it is possible that the relation between height and cancer may simply reflect the long-term effects of prenatal exposures on cancer risk. While none of the studies reporting height-cancer associations have controlled for birth weight, the observation that leg length is the component of height most consistently associated with cancer risk and the fact that associations of birth weight with leg length and trunk length are similar (304) suggest that different pathways may underlie birth weight-cancer and height-cancer associations.
Adult height is also influenced by the timing of puberty, and this too may affect cancer risk. Early menarche is a recognized risk factor for breast cancer (91) , and recently it has been suggested that early attainment of adult height is independently associated with increased breast cancer risk (170) . These risk factors may indicate either a longer exposure of sensitive tissues to sex hormones or an earlier exposure. Early menarche also signals an earlier cessation of growth, since the sex hormone surges associated with puberty result in fusion of the epiphyseal growth plates (286) . Genetic and environmental influences affect the timing of puberty, and while there is some inconsistency in the evidence, most studies indicate that early puberty is associated with short adult stature (302, 305, 306) . On this basis alone, one would predict that short stature would be associated with increased breast cancer risk, whereas the opposite is seen (see table 3 ). Therefore, the height-breast cancer associations are unlikely to arise as a result of the timing of puberty. Furthermore, controlling for age at menarche appears to have little or no effect on height-breast cancer associations (91, 101, 128 ).
Height as a biomarker for biologic mediators of risk
The explanations given above are all based on the assumption that height is simply acting as a marker for another exposure. In the two possible mechanisms discussed below, body size is more directly related to cancer risk. Of course, because they may influence total body size, all of the mechanisms reviewed above may be relevant to the pathways discussed here.
The first pathway links height to the number of cells in the body. Larger bodies contain more cells than smaller bodies, and it has been suggested that the more cells one has the greater the chance that a cell will undergo malignant transformation, escape the body's cancer defense mechanisms, and progress to cancer (307) . Calorie restriction in early life reduces organ cellularity (308) , and it has been proposed that this mechanism might underlie height-cancer associations. Some support for this notion comes from studies demonstrating associations between breast size and cancer risk (128) .
The second pathway links body size to circulating levels of hormones or other substances that influence cancer risk. Two groups of hormones have been investigated: sex hormones and growth hormones. However, no consistent associations have been observed between sex hormone levels and height (309) (310) (311) or cancer risk (312, 313) . More recently, IGFs have been implicated as having a role in the development of cancer, and height may act as a marker for levels of these growth factors. Evidence supporting the role of IGFs in explaining height-cancer associations is outlined below.
Height, Leg Length, and Cancer Risk 335 IGFs, height, and cancer IGF biology. IGFs, particularly IGF-I, play a fundamental role in somatic growth. Cross-sectional studies of children (314, 315) demonstrate that IGF-I levels are associated with stature: Differences of over 20 percent have been observed between the lowest and highest height quartiles (314) . IGF-I is mainly secreted from the liver in response to secretion of pituitary growth hormone, although dietary intake also influences IGF-I levels and some IGF-I synthesis occurs in peripheral tissues. The availability of IGFs to tissues depends on circulating levels of IGF-binding proteins. The principal binding protein for IGF-I is IGF-binding protein 3 (316) .
Epidemiologic evidence. Recent research based on prospective studies has demonstrated that raised levels of IGF-I or low levels of IGF-binding protein 3 are associated with increased risks of prostate cancer (12) (13) (14) , premenopausal breast cancer (15) , and colorectal cancer (16, 17) over prolonged periods of follow-up. In these studies, blood samples were collected many years before the onset of cancer, so it is likely that the raised levels predated the cancers investigated rather than arose as a result of them. It is noteworthy that height-cancer associations are found for these same cancers (tables 1-3). Associations between IGF-I and lung cancer risk have also been reported (317) . Because this finding was restricted to a case-control study in which samples were taken from people with diagnosed lung cancer, the direction of causality is uncertain.
Studies of cancer risk in acromegaly, a condition characterized by high circulating levels of growth hormone (and hence IGF-I), provide further support for the role of the growth hormone-IGF axis in cancer risk (318) (319) (320) . While findings were inconsistent, results from two of the largest prospective studies of people with acromegaly (319, 320) suggested increased risks of malignant melanoma and of gastrointestinal, breast, and hematopoietic cancers.
Further evidence that IGFs may underlie height-cancer associations comes from analyses that have reported on cancer risk in relation to height and its components, leg length and trunk length. Some studies have indicated that leg length is the constituent of height most strongly related to risk of malignancy. In individuals with Laron's syndrome, an inherited condition characterized by low circulating levels of IGF-I, leg length tends to be low in relation to overall height (321, 322) . Thus, it is possible that in the normal population, relative leg length provides an indication of an individual's circulating levels of IGF and his or her cancer risk.
Biologic mechanisms linking IGFs to cancer risk. There are several plausible biologic mechanisms through which IGFs may influence cancer risk (323) (324) (325) . First, IGFs protect damaged cells from apoptosis (cell suicide); hence, higher levels of IGF may enable damaged cells to survive and become cancerous. Second, IGFs are potent stimulators of cell turnover, and the mitotic rate of stem cells is an important determinant of cancer risk. In primate models, growth hormone and IGF-I both stimulate glandular and epithelial cell proliferation, which indicates their potential to initiate and promote neoplasia (326) . Lastly, in vitro studies show that raised levels of IGF-I may amplify the effects of DNA-damaging agents (327) .
Observational and experimental evidence attests to the important role of nutrition, including intrauterine nutrition, in regulating IGF-I (328, 329), with high-energy diets increasing circulating levels and energy restriction decreasing circulating levels. Thus, IGFs could provide a mechanism explaining associations between nutrition and cancer in addition to a mechanism underlying the association between stature and cancer. It is possible that IGF-I levels in adulthood are "programmed" by nutrition in early life, and such programming may be responsible for associations between early life exposures and adult disease.
While there is some attractive evidence in support of a role for IGFs in explaining height-cancer associations, there are some inconsistencies in the research record. In studies of children receiving growth hormone for growth disorders, for example, neither growth hormone deficiency nor growth hormone treatment appears to lead to marked disproportion in leg length relative to height (330) . Furthermore, the strong associations between height and IGF-I reported for children (314, 315) are weaker in adults (14, 331) or are not found in adults (12, 332) . However, it is possible that adult IGF levels reflect patterns of childhood and adolescent growth, such as growth velocity and age at peak height velocity, that are only weakly related to final adult height.
CONCLUSIONS
A large body of literature supports the existence of a real, albeit relatively weak, association between height and cancer risk. Taller individuals appear to be at a 20-60 percent increased risk of a range of cancers. This relation may be explained by genes or by prenatal or childhood exposures, including diet and infection. Further research is required to determine whether the influences of childhood diet on growth and circulating growth factor levels underlie the observed associations. Observations that height-cancer associations differ depending on an individual's weight require further detailed review, and mechanisms for observed interactions should be investigated.
The finding in some studies that leg length is the component of height that is generating the height-cancer associations requires replication. Furthermore, the differential association of growth factor levels with leg length and trunk length should be investigated. Such research might provide insight into periods of life that are critical for the development of cancer risk.
From the population perspective, one must remember that while greater stature is associated with increased cancer mortality, it has long been recognized that taller individuals generally have lower overall mortality rates than shorter people (333, 334) . This is largely because associations between height and cardiorespiratory disease point in a direction opposite that of associations with cancer (2, 29) . However, understanding the biologic mechanisms through which height and cancer risk are linked may lead both to possible interventions and to an appreciation of critical times in the development of cancer risk in childhood and adolescence.
